University of Texas System

Dnatrix, Inc.

Other

Regeneron Pharmaceuticals, Inc.

W K Alfred Yung

Candelaria Gomez-Manzano

Charles A Conrad

Juan Fueyo-Margareto

Frank Tufaro

Frederick Lang, Jr

Juan Fueyo

Hong Jiang

Sean V Tavtigian

Jesse M Cedarbaum

Jocelyn Holash

Peter A Steck

Mark A Pershouse

Samar A Jasser

Amy Heimberger

Victor Krasnykh

The present invention is directed to adenoviruses for use in cancer therapy which comprise one or more heterologous nucleic acid sequences encoding a tumor antigen, whereby the adenovirus expresses the tumor antigen(s) on its surface.

Adenoviruses expressing heterologous tumor-associated antigens

Certain embodiments include the enhancement of effectiveness for an adenoviral cancer therapy.

Adenovirus and immunomodulator combination therapy

The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.

Biomarkers and combination therapies using oncolytic virus and immunomodulation

The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.

Oncolytic adenovirus armed with therapeutic genes

Methods for treating a human patient suffering from a brain tumor, including glioblastoma, by administering an effective amount of a vascular endothelial growth factor (VEGF) inhibitor to the human patient. The VEGF inhibitor is a VEGF antagonist protein comprising a dimeric protein having two fusion polypeptides having the sequence of SEQ ID NO:2.

Use of VEGF antagonists for the treatment of malignant gliomas

A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed.

Tumor suppressor designated TS10Q23.3

Growing community of inventors

Houston, TX, United States of America

W K Alfred Yung